We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to sell.

Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical ...

Allogene Therapeutics, a clinical-stage biotechnology company, will present updated data from its Phase 1 TRAVERSE trial of ALLO-316 at the 2025 ASCO Annual Meeting in Chicago. The study focuses ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in biological products trading at $1.93 per share, announced the upcoming departure of Timothy Moore, an executive ...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the ...

May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR TTM) products for cancer ...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the ...